Briacell receives $2.05M Bria-PROS+ research grant

Dr. William Williams reports BRIACELL AWARDED $2 MILLION NCI GRANT TO ADVANCE BRIA-PROS+ IN PROSTATE CANCER The National Cancer Institute, the U.S. federal government's principal agency for cancer research and training, has awarded Briacell Therapeutics Corp. a research grant of $2,054,651 to advance Bria-PROS+, Briacell's next-generation personalized off-the-shelf immunotherapy for prostate cancer. The non-dilutive grant, titled "Phase 1/2a clinical trial to investigate Bria-PROS+ in patients with metastatic prostate cancer," will be used to complete manufacturing of Bria-PROS+ and to finance the coming phase 1/2a study in patients with advanced prostate cancer. "Despite recent advances in the management of metastatic hormone-sensitive prostate cancer, most patients will progress with significant pain and suffering and limited treatment options," stated Dr. William Oh, MD, director of precision medicine, Yale Cancer Center, and principal investigator on the coming phase 1/2a clinical study of Bria-PROS+ in advanced prostate cancer. "We are grateful to the NCI for recognizing the urgency for this unmet medical need and supporting Briacell's breakthrough immunotherapy." "This prestigious award will help expedite the clinical development of Bria-PROS+ and is significant validation of our next-generation novel personalized immunotherapy approach," added Dr. William V. Williams, Briacell's president and chief executive officer. "The Bria-OTS+ platform was designed to overcome the complexity, cost and delays of traditional personalized cancer treatments," noted Miguel Lopez-Lago, PhD, Briacell's chief scientific officer. "We believe it will constitute a significant advancement in personalized cancer care." About Briacell Therapeutics Corp. Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. We seek Safe Harbor.